---

Clinical Efficacy of Placentrex Injection in Pelvic Inflammatory Disease

---

Original Article

Author Details : Prameela, Kavya D Sharma

Volume : 3, Issue : 1, Year : 2016

Article Page : 65-67

Suggest article by email

Get Permission

---

Abstract

Pelvic inflammatory disease (PID) is one of the most frequent infections seen in reproductive age group and is associated with major clinical and pelvic health problem. It is Infection & inflammation of upper genital tract organs typically involving fallopian tubes, ovaries & surrounding structures. PID is polymicrobial in nature and is associated with different etiological agents. Clinical presentations may vary from mild to severe. No specific signs and symptoms are pathognomic of PID. Laboratory tests are also poor predictors of PID. There may be subclinical symptoms and patient later may present with infertility. CDC recommends treatment for even mild cases of PID. Therapeutic goal in management of PID is to prevent chronic residual disease. Failure of antibiotic therapy to prevent sequelae of salpingitis reflects the emphasis of additional therapy along with antibiotics. Placentrex is a drug containing Peptides (FNP-III, CRF), Nucleotides (PDRN) & Glutamate and is derived from an extract of fresh term, healthy, human placenta. It has significant anti inflammatory effect involving chemical mediators of immunological response. Effect of placentrex is well documented in wound healing1 and in treatment of burns and radiation effects 2. It has been recommended for prescription for PID but there is not much data in literature regarding the efficacy in PID. So we conducted a trial to find efficacy of placentrex in comparision with azithromycin for the treatment of PID.

Keywords: Placentrex Injection Pelvic Inflammatory Disease, Azithromycin menstrual irregularity, Dysmennorrhoea

How to cite : Prameela, Sharma K D, Clinical Efficacy of Placentrex Injection in Pelvic Inflammatory Disease. Indian J Obstet Gynecol Res 2016;3(1):65-67

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.